Kangji Medical Holdings Yönetim

Yönetim kriter kontrolleri 4/4

Kangji Medical Holdings CEO'su Ming Zhong, Aug2004 tarihinde atandı, in görev süresi 20.25 yıldır. in toplam yıllık tazminatı CN¥ 1.23M olup, şirket hissesi ve opsiyonları dahil olmak üzere 96.2% maaş ve 3.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 33.78% ine doğrudan sahiptir ve bu hisseler HK$ 2.43B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 4.7 yıldır.

Anahtar bilgiler

Ming Zhong

İcra Kurulu Başkanı

CN¥1.2m

Toplam tazminat

CEO maaş yüzdesi	96.2%
CEO görev süresi	20.3yrs
CEO sahipliği	33.8%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	4.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Ming Zhong'un ücretlendirmesi Kangji Medical Holdings'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	CN¥534m
Mar 31 2024	n/a	n/a	CN¥519m
Dec 31 2023	CN¥1m	CN¥1m	CN¥504m
Sep 30 2023	n/a	n/a	CN¥540m
Jun 30 2023	n/a	n/a	CN¥576m
Mar 31 2023	n/a	n/a	CN¥528m
Dec 31 2022	CN¥1m	CN¥1m	CN¥479m
Sep 30 2022	n/a	n/a	CN¥447m
Jun 30 2022	n/a	n/a	CN¥415m
Mar 31 2022	n/a	n/a	CN¥436m
Dec 31 2021	CN¥1m	CN¥990k	CN¥457m

Tazminat ve Piyasa: Ming 'nin toplam tazminatı ($USD 170.90K ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 479.12K ).

Tazminat ve Kazançlar: Ming 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Ming Zhong (48 yo)

20.3yrs

Görev süresi

CN¥1,232,000

Tazminat

Mr. Ming Zhong serves as Executive Director of Kangji Medical Holdings Limited since March 7, 2020 and Chief Executive Officer since August 24, 2004 and is its Executive Chairman since May 2024. He is main...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ming Zhong	Executive Chairman of the Board & CEO	20.3yrs	CN¥1.23m	33.78% HK$ 2.4b
Yinguang Shentu	Vice GM & Executive Director	8yrs	CN¥1.03m	19.14% HK$ 1.4b
Zixin Yin	Vice GM & Executive Director	4.7yrs	CN¥1.94m	Veri yok
Yanyu Hu	Chief Financial Officer	1.2yrs	Veri yok	Veri yok
Jianyong Ju	Head of Domestic Sales & Marketing	3.8yrs	Veri yok	Veri yok
Siu Keung Wan	Company Secretary	2.5yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

45.5yo

Ortalama Yaş

Deneyimli Yönetim: 9997 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ming Zhong	Executive Chairman of the Board & CEO	4.8yrs	CN¥1.23m	33.78% HK$ 2.4b
Yinguang Shentu	Vice GM & Executive Director	4.7yrs	CN¥1.03m	19.14% HK$ 1.4b
Zixin Yin	Vice GM & Executive Director	2.6yrs	CN¥1.94m	Veri yok
Jian Guo	Independent Non-Executive Director	4.7yrs	CN¥102.00k	Veri yok
Lydia Cai	Non-Executive Director	4.7yrs	Veri yok	Veri yok
Weibo Chen	Independent Non-Executive Director	4.7yrs	CN¥102.00k	Veri yok
Feng Jiang	Independent Non-Executive Director	4.7yrs	CN¥102.00k	Veri yok

4.7yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 9997 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.7 yıldır).

Kangji Medical Holdings Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Kangji Medical Holdings Limited, Annual General Meeting, May 27, 2024

Kangji Medical Holdings Limited Announces CFO Changes

Kangji Medical Holdings Limited Announces the Resignation of Frances Fang Chovanec as Executive Director, Member of Environmental, Social and Governance Committee with Effective from September 15, 2023

Less than half of directors are independent

Kangji Medical Holdings Limited Announces Executive Changes

Less than half of directors are independent

Recent updates

First half 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.22 in 1H 2023)

First half 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.22 in 1H 2023)

Kangji Medical Holdings Limited to Report First Half, 2024 Results on Aug 20, 2024

Kangji Medical Holdings Limited Approves Special Dividend for the Year Ended 31 December 2023, Payable on 18 July 2024

Investor sentiment deteriorates as stock falls 26%

Upcoming dividend of CN¥1.40 per share

Full year 2023 earnings released: EPS: CN¥0.43 (vs CN¥0.40 in FY 2022)

Kangji Medical Holdings Limited Proposes Special Dividend for the Year Ended December 31, 2023

Dividend of CN¥1.40 announced

Kangji Medical Holdings Limited, Annual General Meeting, May 27, 2024

Investor sentiment improves as stock rises 17%

Kangji Medical Holdings Limited Announces CFO Changes

Kangji Medical Holdings Limited Announces the Resignation of Frances Fang Chovanec as Executive Director, Member of Environmental, Social and Governance Committee with Effective from September 15, 2023

First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.13 in 1H 2022)

Kangji Medical Holdings Limited to Report First Half, 2023 Results on Aug 29, 2023

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Kangji Medical Holdings Limited Approves Payment of Final Dividend for the Year Ended December 31, 2022, Payment Date Is 10 July 2023

Full year 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.37 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.16 in 1H 2021)

Kangji Medical Holdings Limited to Report First Half, 2022 Results on Aug 25, 2022

Kangji Medical Holdings Limited Approves Final Dividend for the Year Ended December 31, 2021, Payment date is 08 July 2022

Kangji Medical Holdings Limited Approves Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.17 per share

Kangji Medical Holdings Limited Announces Executive Changes

Full year 2021 earnings released: EPS: CN¥0.37 (vs CN¥0.26 in FY 2020)

Less than half of directors are independent

Kangji Medical Holdings Limited to Report Fiscal Year 2021 Results on Mar 22, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First half 2021 earnings released: EPS CN¥0.16 (vs CN¥0.12 in 1H 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Kangji Medical Holdings Limited Approves Final Dividend for the Year Ended December 31, 2020

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.20 in FY 2019)

Kangji Medical Holdings Limited Proposes Final Dividend for the Year Ended December 31, 2020

Investor sentiment improved over the past week

Full year 2020 earnings released

Kangji Medical Holdings Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

Investor sentiment deteriorated over the past week

New 90-day low: HK$10.88

Investor sentiment deteriorated over the past week

New 90-day low: HK$12.16

Investor sentiment deteriorated over the past week

New 90-day low: HK$13.86

Market pulls back on stock over the past week

Kangji Medical Holdings Limited Appoints Frances Fang Chovanec as Executive Director

First half earnings released

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş